{"transactions":[{"id":836089,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-18T20:11:17.000Z","date":"2026-03-16","kind":"exercise","planned":false,"acquired":true,"shares":11575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date."}],"balance_after":11575,"derivative":{"underlying":"Common Stock","underlying_shares":11575},"source":{"system":"sec-edgar","filing":"0000805928-26-000048","document":"wk-form4_1773864674.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000048/wk-form4_1773864674.xml","form_type":"4"}},{"id":836088,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-18T20:11:17.000Z","date":"2026-03-16","kind":"exercise","planned":false,"acquired":true,"shares":6363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates."}],"balance_after":6363,"derivative":{"underlying":"Common Stock","underlying_shares":6363},"source":{"system":"sec-edgar","filing":"0000805928-26-000048","document":"wk-form4_1773864674.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000048/wk-form4_1773864674.xml","form_type":"4"}},{"id":836087,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:11:17.000Z","date":"2026-03-16","kind":"sale","planned":false,"acquired":false,"shares":5221,"price":32.84,"value":171457.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale."}],"balance_after":262781,"source":{"system":"sec-edgar","filing":"0000805928-26-000048","document":"wk-form4_1773864674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000048/wk-form4_1773864674.xml","form_type":"4"}},{"id":836086,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:11:17.000Z","date":"2026-03-16","kind":"exercise","planned":false,"acquired":true,"shares":11575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units (\"RSUs\") that vested on March 16, 2026."}],"balance_after":268002,"source":{"system":"sec-edgar","filing":"0000805928-26-000048","document":"wk-form4_1773864674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000048/wk-form4_1773864674.xml","form_type":"4"}},{"id":836085,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:11:17.000Z","date":"2026-03-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2870,"price":32.84,"value":94250.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale."}],"balance_after":256427,"source":{"system":"sec-edgar","filing":"0000805928-26-000048","document":"wk-form4_1773864674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000048/wk-form4_1773864674.xml","form_type":"4"}},{"id":836084,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:11:17.000Z","date":"2026-03-16","kind":"exercise","planned":false,"acquired":true,"shares":6363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units (\"RSUs\") that vested on March 16, 2026."}],"balance_after":259297,"source":{"system":"sec-edgar","filing":"0000805928-26-000048","document":"wk-form4_1773864674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000048/wk-form4_1773864674.xml","form_type":"4"}},{"id":875715,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-02T23:16:14.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":23000,"derivative":{"underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000805928-26-000043","document":"wk-form4_1772493371.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000043/wk-form4_1772493371.xml","form_type":"4"}},{"id":875714,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2026-03-02T23:16:14.000Z","date":"2026-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":11276,"price":30.65,"value":345609.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of restricted stock units (\"RSUs\")."}],"balance_after":252934,"source":{"system":"sec-edgar","filing":"0000805928-26-000043","document":"wk-form4_1772493371.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000043/wk-form4_1772493371.xml","form_type":"4"}},{"id":875713,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2026-03-02T23:16:14.000Z","date":"2026-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":10702,"price":31.9,"value":341393.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of performance stock units (\"PSUs\")."}],"balance_after":264210,"source":{"system":"sec-edgar","filing":"0000805928-26-000043","document":"wk-form4_1772493371.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000043/wk-form4_1772493371.xml","form_type":"4"}},{"id":875712,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2026-03-02T23:16:14.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":33780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria."}],"balance_after":274912,"source":{"system":"sec-edgar","filing":"0000805928-26-000043","document":"wk-form4_1772493371.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000043/wk-form4_1772493371.xml","form_type":"4"}},{"id":975260,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-12-10T22:20:27.000Z","date":"2025-12-09","kind":"sale","planned":false,"acquired":false,"shares":19517,"price":31.208,"value":609086.536,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units on December 4, 2025. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold on December 9, 2025, in multiple transactions at $31.208 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":241132,"source":{"system":"sec-edgar","filing":"0000805928-25-000165","document":"wk-form4_1765405224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000165/wk-form4_1765405224.xml","form_type":"4"}},{"id":979702,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-12-05T21:55:14.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares issued upon the attainment of certain performance criteria."}],"balance_after":260649,"source":{"system":"sec-edgar","filing":"0000805928-25-000150","document":"wk-form4_1764971712.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000150/wk-form4_1764971712.xml","form_type":"4"}},{"id":1039895,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-09-16T21:22:01.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":1137,"price":16.29,"value":18521.73,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units (\"PSUs\") on September 13, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":220649,"source":{"system":"sec-edgar","filing":"0000805928-25-000116","document":"wk-form4_1758057719.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000116/wk-form4_1758057719.xml","form_type":"4"}},{"id":1039894,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-09-16T21:22:01.000Z","date":"2025-09-13","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares issued upon the attainment of certain performance criteria."}],"balance_after":221786,"source":{"system":"sec-edgar","filing":"0000805928-25-000116","document":"wk-form4_1758057719.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000116/wk-form4_1758057719.xml","form_type":"4"}},{"id":1191658,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-26T20:52:55.000Z","date":"2025-03-25","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":38000,"derivative":{"underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0000805928-25-000048","document":"wk-form4_1743022368.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000048/wk-form4_1743022368.xml","form_type":"4"}},{"id":1197785,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-19T21:24:10.000Z","date":"2025-03-16","kind":"exercise","planned":false,"acquired":false,"shares":23150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":23150,"derivative":{"underlying":"Common Stock","underlying_shares":23150},"source":{"system":"sec-edgar","filing":"0000805928-25-000041","document":"wk-form4_1742419444.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000041/wk-form4_1742419444.xml","form_type":"4"}},{"id":1197784,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-19T21:24:10.000Z","date":"2025-03-16","kind":"exercise","planned":false,"acquired":false,"shares":6362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":6363,"derivative":{"underlying":"Common Stock","underlying_shares":6362},"source":{"system":"sec-edgar","filing":"0000805928-25-000041","document":"wk-form4_1742419444.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000041/wk-form4_1742419444.xml","form_type":"4"}},{"id":1197783,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-19T21:24:10.000Z","date":"2025-03-16","kind":"exercise","planned":false,"acquired":false,"shares":2950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2950},"source":{"system":"sec-edgar","filing":"0000805928-25-000041","document":"wk-form4_1742419444.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000041/wk-form4_1742419444.xml","form_type":"4"}},{"id":1197782,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-03-19T21:24:10.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":15111,"price":17.5,"value":264442.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on March 16, 2025. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold on March 19, 2025 in multiple transactions at  $17.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":217762,"source":{"system":"sec-edgar","filing":"0000805928-25-000041","document":"wk-form4_1742419444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000041/wk-form4_1742419444.xml","form_type":"4"}},{"id":1197781,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-03-19T21:24:10.000Z","date":"2025-03-16","kind":"exercise","planned":false,"acquired":true,"shares":23150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of March 16, 2025."}],"balance_after":232873,"source":{"system":"sec-edgar","filing":"0000805928-25-000041","document":"wk-form4_1742419444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000041/wk-form4_1742419444.xml","form_type":"4"}},{"id":1197780,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-03-19T21:24:10.000Z","date":"2025-03-16","kind":"exercise","planned":false,"acquired":true,"shares":6362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of March 16, 2025."}],"balance_after":209723,"source":{"system":"sec-edgar","filing":"0000805928-25-000041","document":"wk-form4_1742419444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000041/wk-form4_1742419444.xml","form_type":"4"}},{"id":1197779,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-03-19T21:24:10.000Z","date":"2025-03-16","kind":"exercise","planned":false,"acquired":true,"shares":2950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of March 16, 2025."}],"balance_after":203361,"source":{"system":"sec-edgar","filing":"0000805928-25-000041","document":"wk-form4_1742419444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000041/wk-form4_1742419444.xml","form_type":"4"}},{"id":1233075,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-03-05T00:22:37.000Z","date":"2025-03-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":8296,"price":18.35,"value":152231.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units (\"PSUs\") on February 28, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold on March 4, 2025 in multiple transactions at prices ranging from $18.34 to $18.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":201005,"source":{"system":"sec-edgar","filing":"0000805928-25-000028","document":"wk-form4_1741134151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000028/wk-form4_1741134151.xml","form_type":"4"}},{"id":1233074,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-03-05T00:22:37.000Z","date":"2025-02-28","kind":"exercise","planned":false,"acquired":true,"shares":24799,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares issued upon the attainment of certain performance criteria."}],"balance_after":209301,"source":{"system":"sec-edgar","filing":"0000805928-25-000028","document":"wk-form4_1741134151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000028/wk-form4_1741134151.xml","form_type":"4"}},{"id":1244475,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-02-26T21:23:19.000Z","date":"2025-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":972,"price":16.5,"value":16038.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units (\"PSUs\") on February 22, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold on February 25, 2025  in multiple transactions at prices ranging from $16.42 to $17.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":184502,"source":{"system":"sec-edgar","filing":"0000805928-25-000018","document":"wk-form4_1740604988.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000018/wk-form4_1740604988.xml","form_type":"4"}},{"id":1244474,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2025-02-26T21:23:19.000Z","date":"2025-02-22","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares issued upon the attainment of certain performance criteria."}],"balance_after":185474,"source":{"system":"sec-edgar","filing":"0000805928-25-000018","document":"wk-form4_1740604988.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000018/wk-form4_1740604988.xml","form_type":"4"}},{"id":1408128,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2024-09-13T20:30:37.000Z","date":"2024-09-13","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares  issued upon the attainment of certain performance criteria."}],"balance_after":179974,"source":{"system":"sec-edgar","filing":"0000805928-24-000129","document":"wk-form4_1726259429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000129/wk-form4_1726259429.xml","form_type":"4"}},{"id":1562629,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-26T01:40:28.000Z","date":"2024-03-16","kind":"exercise","planned":false,"acquired":false,"shares":12725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":12725,"derivative":{"underlying":"Common Stock","underlying_shares":12725},"source":{"system":"sec-edgar","filing":"0000805928-24-000049","document":"wk-form4_1711417219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000049/wk-form4_1711417219.xml","form_type":"4"}},{"id":1562628,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-26T01:40:28.000Z","date":"2024-03-16","kind":"exercise","planned":false,"acquired":false,"shares":2950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":2950,"derivative":{"underlying":"Common Stock","underlying_shares":2950},"source":{"system":"sec-edgar","filing":"0000805928-24-000049","document":"wk-form4_1711417219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000049/wk-form4_1711417219.xml","form_type":"4"}},{"id":1562627,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-26T01:40:28.000Z","date":"2024-03-16","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000805928-24-000049","document":"wk-form4_1711417219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000049/wk-form4_1711417219.xml","form_type":"4"}},{"id":1562626,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2024-03-26T01:40:28.000Z","date":"2024-03-21","kind":"sale","planned":false,"acquired":false,"shares":3141,"price":7.68,"value":24122.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":177474,"source":{"system":"sec-edgar","filing":"0000805928-24-000049","document":"wk-form4_1711417219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000049/wk-form4_1711417219.xml","form_type":"4"}},{"id":1562625,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2024-03-26T01:40:28.000Z","date":"2024-03-16","kind":"exercise","planned":false,"acquired":true,"shares":12725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of March 16, 2024."}],"balance_after":180615,"source":{"system":"sec-edgar","filing":"0000805928-24-000049","document":"wk-form4_1711417219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000049/wk-form4_1711417219.xml","form_type":"4"}},{"id":1562624,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2024-03-26T01:40:28.000Z","date":"2024-03-21","kind":"sale","planned":false,"acquired":false,"shares":721,"price":7.68,"value":5537.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":167890,"source":{"system":"sec-edgar","filing":"0000805928-24-000049","document":"wk-form4_1711417219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000049/wk-form4_1711417219.xml","form_type":"4"}},{"id":1562623,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2024-03-26T01:40:28.000Z","date":"2024-03-16","kind":"exercise","planned":false,"acquired":true,"shares":2950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of March 16, 2024."}],"balance_after":168611,"source":{"system":"sec-edgar","filing":"0000805928-24-000049","document":"wk-form4_1711417219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000049/wk-form4_1711417219.xml","form_type":"4"}},{"id":1562622,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2024-03-26T01:40:28.000Z","date":"2024-03-21","kind":"sale","planned":false,"acquired":false,"shares":716,"price":7.68,"value":5498.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":165661,"source":{"system":"sec-edgar","filing":"0000805928-24-000049","document":"wk-form4_1711417219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000049/wk-form4_1711417219.xml","form_type":"4"}},{"id":1562621,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2024-03-26T01:40:28.000Z","date":"2024-03-16","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of March 16, 2024."}],"balance_after":166377,"source":{"system":"sec-edgar","filing":"0000805928-24-000049","document":"wk-form4_1711417219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000049/wk-form4_1711417219.xml","form_type":"4"}},{"id":1600357,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2024-03-05T21:33:27.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."}],"balance_after":163377,"source":{"system":"sec-edgar","filing":"0000805928-24-000031","document":"wk-form4_1709674382.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000031/wk-form4_1709674382.xml","form_type":"4"}},{"id":1623748,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Performance Stock Units","published_at":"2024-02-23T21:02:19.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":68600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the performance stock units (\"PSUs\") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan (\"Plan\") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the \"target\" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the performance stock units (\"PSUs\") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan (\"Plan\") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the \"target\" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents the performance stock units (\"PSUs\") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan (\"Plan\") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the \"target\" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number."}],"balance_after":68600,"derivative":{"underlying":"Common Stock","underlying_shares":68600},"source":{"system":"sec-edgar","filing":"0001209191-24-003889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000120919124003889/doc4.xml","form_type":"4"}},{"id":1760864,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2023-10-14T00:29:47.000Z","date":"2023-10-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":864,"price":4.04,"value":3490.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale."}],"balance_after":113377,"source":{"system":"sec-edgar","filing":"0000805928-23-000140","document":"wk-form4_1697243379.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000140/wk-form4_1697243379.xml","form_type":"4"}},{"id":1760863,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2023-10-14T00:29:47.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":1579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares issued upon the attainment of certain performance criteria."}],"balance_after":114241,"source":{"system":"sec-edgar","filing":"0000805928-23-000140","document":"wk-form4_1697243379.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000140/wk-form4_1697243379.xml","form_type":"4"}},{"id":1945298,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Restricted Stock Units","published_at":"2023-03-21T01:08:45.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":46300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":46300,"derivative":{"underlying":"Common Stock","underlying_shares":46300},"source":{"system":"sec-edgar","filing":"0000805928-23-000030","document":"wf-form4_167936091488272.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000030/wf-form4_167936091488272.xml","form_type":"4"}},{"id":1945297,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Employee Stock Option (right to purchase)","published_at":"2023-03-21T01:08:45.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":64000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter."}],"balance_after":64000,"derivative":{"exercise_price":8.27,"expiration_date":"2023-03-16","underlying":"Common Stock","underlying_shares":64000},"source":{"system":"sec-edgar","filing":"0000805928-23-000030","document":"wf-form4_167936091488272.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000030/wf-form4_167936091488272.xml","form_type":"4"}},{"id":1945296,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Restricted Stock Units","published_at":"2023-03-21T01:08:45.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000805928-23-000030","document":"wf-form4_167936091488272.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000030/wf-form4_167936091488272.xml","form_type":"4"}},{"id":1945295,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Restricted Stock Units","published_at":"2023-03-21T01:08:45.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":5900,"derivative":{"underlying":"Common Stock","underlying_shares":5900},"source":{"system":"sec-edgar","filing":"0000805928-23-000030","document":"wf-form4_167936091488272.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000030/wf-form4_167936091488272.xml","form_type":"4"}},{"id":1945294,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2023-03-21T01:08:45.000Z","date":"2023-03-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":934,"price":8.27,"value":7724.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":112662,"source":{"system":"sec-edgar","filing":"0000805928-23-000030","document":"wf-form4_167936091488272.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000030/wf-form4_167936091488272.xml","form_type":"4"}},{"id":1945293,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2023-03-21T01:08:45.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of March 16, 2023."}],"balance_after":113596,"source":{"system":"sec-edgar","filing":"0000805928-23-000030","document":"wf-form4_167936091488272.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000030/wf-form4_167936091488272.xml","form_type":"4"}},{"id":1945292,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2023-03-21T01:08:45.000Z","date":"2023-03-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1835,"price":8.27,"value":15175.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":110596,"source":{"system":"sec-edgar","filing":"0000805928-23-000030","document":"wf-form4_167936091488272.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000030/wf-form4_167936091488272.xml","form_type":"4"}},{"id":1945291,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2023-03-21T01:08:45.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of March 16, 2023."}],"balance_after":112431,"source":{"system":"sec-edgar","filing":"0000805928-23-000030","document":"wf-form4_167936091488272.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000030/wf-form4_167936091488272.xml","form_type":"4"}},{"id":2075282,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Restricted Stock Units","published_at":"2022-12-30T01:56:43.000Z","date":"2022-12-27","kind":"exercise","acquired":true,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0000805928-22-000145","document":"wf-form4_167236538787713.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000145/wf-form4_167236538787713.xml","form_type":"4"}},{"id":2075281,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-12-30T01:56:43.000Z","date":"2022-12-27","kind":"tax_withholding","acquired":false,"shares":187,"price":9.44,"value":1765.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":106531,"source":{"system":"sec-edgar","filing":"0000805928-22-000145","document":"wf-form4_167236538787713.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000145/wf-form4_167236538787713.xml","form_type":"4"}},{"id":2075280,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-12-30T01:56:43.000Z","date":"2022-12-27","kind":"exercise","acquired":true,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This reflects the number of restricted stock units that vested on December 27, 2022."}],"balance_after":106718,"source":{"system":"sec-edgar","filing":"0000805928-22-000145","document":"wf-form4_167236538787713.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000145/wf-form4_167236538787713.xml","form_type":"4"}},{"id":2075829,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-12-29T02:34:50.000Z","date":"2022-12-27","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.09,"exercise_date":"2016-12-28","expiration_date":"2022-12-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000805928-22-000133","document":"wf-form4_167228127578446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000133/wf-form4_167228127578446.xml","form_type":"4"}},{"id":2075828,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-12-29T02:34:50.000Z","date":"2022-12-27","kind":"tax_withholding","acquired":false,"shares":10784,"price":9.44,"value":101800.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form is being filed to report the exercise of a stock option for a total of 20,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock, the Reporting Person, on a net basis, acquired ownership of an additional 9,216 shares of common stock."}],"balance_after":105968,"source":{"system":"sec-edgar","filing":"0000805928-22-000133","document":"wf-form4_167228127578446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000133/wf-form4_167228127578446.xml","form_type":"4"}},{"id":2075827,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-12-29T02:34:50.000Z","date":"2022-12-27","kind":"exercise","acquired":true,"shares":20000,"price":5.09,"value":101800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form is being filed to report the exercise of a stock option for a total of 20,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock, the Reporting Person, on a net basis, acquired ownership of an additional 9,216 shares of common stock."}],"balance_after":116752,"source":{"system":"sec-edgar","filing":"0000805928-22-000133","document":"wf-form4_167228127578446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000133/wf-form4_167228127578446.xml","form_type":"4"}},{"id":2204830,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-07-20T20:01:37.000Z","date":"2022-07-19","kind":"disposition_to_issuer","acquired":false,"shares":405,"price":8.4,"value":3402.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022."}],"balance_after":96752,"source":{"system":"sec-edgar","filing":"0000805928-22-000092","document":"wf-form4_165834728313660.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000092/wf-form4_165834728313660.xml","form_type":"4"}},{"id":2204829,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-07-20T20:01:37.000Z","date":"2022-07-18","kind":"grant","acquired":true,"shares":1579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria."}],"balance_after":94157,"source":{"system":"sec-edgar","filing":"0000805928-22-000092","document":"wf-form4_165834728313660.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000092/wf-form4_165834728313660.xml","form_type":"4"}},{"id":2325646,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Employee Stock Option (right to purchase)","published_at":"2022-03-18T20:03:13.000Z","date":"2022-03-16","kind":"grant","acquired":true,"shares":23738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter."}],"balance_after":23738,"derivative":{"exercise_price":8.2,"expiration_date":"2032-03-16","underlying":"Common Stock","underlying_shares":23738},"source":{"system":"sec-edgar","filing":"0000805928-22-000028","document":"wf-form4_164763377704238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000028/wf-form4_164763377704238.xml","form_type":"4"}},{"id":2325645,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Restricted Stock Units","published_at":"2022-03-18T20:03:13.000Z","date":"2022-03-16","kind":"grant","acquired":true,"shares":25450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":25450,"derivative":{"underlying":"Common Stock","underlying_shares":25450},"source":{"system":"sec-edgar","filing":"0000805928-22-000028","document":"wf-form4_164763377704238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000028/wf-form4_164763377704238.xml","form_type":"4"}},{"id":2325644,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Restricted Stock Units","published_at":"2022-03-18T20:03:13.000Z","date":"2022-03-16","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":6000,"derivative":{"exercise_date":"2024-03-16","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000805928-22-000028","document":"wf-form4_164763377704238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000028/wf-form4_164763377704238.xml","form_type":"4"}},{"id":2325643,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-03-18T20:03:13.000Z","date":"2022-03-16","kind":"tax_withholding","acquired":false,"shares":1497,"price":7.97,"value":11931.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":92578,"source":{"system":"sec-edgar","filing":"0000805928-22-000028","document":"wf-form4_164763377704238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000028/wf-form4_164763377704238.xml","form_type":"4"}},{"id":2325642,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-03-18T20:03:13.000Z","date":"2022-03-16","kind":"exercise","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of March 16, 2022."}],"balance_after":94075,"source":{"system":"sec-edgar","filing":"0000805928-22-000028","document":"wf-form4_164763377704238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000028/wf-form4_164763377704238.xml","form_type":"4"}},{"id":2390258,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-02-17T21:05:31.000Z","date":"2022-02-15","kind":"tax_withholding","acquired":false,"shares":357,"price":8.42,"value":3005.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022."}],"balance_after":88075,"source":{"system":"sec-edgar","filing":"0000805928-22-000008","document":"wf-form4_164513189026580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000008/wf-form4_164513189026580.xml","form_type":"4"}},{"id":2390257,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2022-02-17T21:05:31.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":1181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2 shares acquired under the Axogen stock purchase plan on December 31, 2021."}],"balance_after":88432,"source":{"system":"sec-edgar","filing":"0000805928-22-000008","document":"wf-form4_164513189026580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000008/wf-form4_164513189026580.xml","form_type":"4"}},{"id":2457509,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Restricted Stock Units","published_at":"2021-12-29T21:17:39.000Z","date":"2021-12-27","kind":"exercise","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":750,"derivative":{"exercise_date":"2022-12-27","expiration_date":"2022-12-27","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0000805928-21-000179","document":"wf-form4_164081264670254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000179/wf-form4_164081264670254.xml","form_type":"4"}},{"id":2457508,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2021-12-29T21:17:39.000Z","date":"2021-12-27","kind":"tax_withholding","acquired":false,"shares":187,"price":9.74,"value":1821.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":87249,"source":{"system":"sec-edgar","filing":"0000805928-21-000179","document":"wf-form4_164081264670254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000179/wf-form4_164081264670254.xml","form_type":"4"}},{"id":2457507,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2021-12-29T21:17:39.000Z","date":"2021-12-27","kind":"exercise","acquired":true,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that vested on December 27, 2021."}],"balance_after":87436,"source":{"system":"sec-edgar","filing":"0000805928-21-000179","document":"wf-form4_164081264670254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000179/wf-form4_164081264670254.xml","form_type":"4"}},{"id":2461729,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Restricted Stock Units","published_at":"2021-12-22T21:03:21.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2021-12-20","expiration_date":"2021-12-20","underlying":"Common Stock","underlying_shares":575},"source":{"system":"sec-edgar","filing":"0000805928-21-000173","document":"wf-form4_164020697971757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000173/wf-form4_164020697971757.xml","form_type":"4"}},{"id":2461728,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2021-12-22T21:03:21.000Z","date":"2021-12-20","kind":"tax_withholding","acquired":false,"shares":144,"price":9.24,"value":1330.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units on December 18, 2021. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":86686,"source":{"system":"sec-edgar","filing":"0000805928-21-000173","document":"wf-form4_164020697971757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000173/wf-form4_164020697971757.xml","form_type":"4"}},{"id":2461727,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2021-12-22T21:03:21.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of December 18, 2021."}],"balance_after":86830,"source":{"system":"sec-edgar","filing":"0000805928-21-000173","document":"wf-form4_164020697971757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000173/wf-form4_164020697971757.xml","form_type":"4"}},{"id":2468812,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-12-17T21:02:34.000Z","date":"2021-12-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.67,"exercise_date":"2018-12-29","expiration_date":"2021-12-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000805928-21-000172","document":"wf-form4_163977493108416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000172/wf-form4_163977493108416.xml","form_type":"4"}},{"id":2468811,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2021-12-17T21:02:34.000Z","date":"2021-12-15","kind":"tax_withholding","acquired":false,"shares":4171,"price":8.8,"value":36704.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule16b-3."}],"balance_after":86255,"source":{"system":"sec-edgar","filing":"0000805928-21-000172","document":"wf-form4_163977493108416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000172/wf-form4_163977493108416.xml","form_type":"4"}},{"id":2468810,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2021-12-17T21:02:34.000Z","date":"2021-12-15","kind":"exercise","acquired":true,"shares":10000,"price":3.67,"value":36700.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that became vested as of December 29, 2018."}],"balance_after":90426,"source":{"system":"sec-edgar","filing":"0000805928-21-000172","document":"wf-form4_163977493108416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000172/wf-form4_163977493108416.xml","form_type":"4"}},{"id":2628777,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2021-07-21T20:16:16.000Z","date":"2021-07-20","kind":"tax_withholding","acquired":false,"shares":392,"price":19.2,"value":7526.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021."}],"balance_after":80426,"source":{"system":"sec-edgar","filing":"0000805928-21-000148","document":"wf-form4_162689855941312.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000148/wf-form4_162689855941312.xml","form_type":"4"}},{"id":2628776,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Peripheral Nerve Science"}}],"security":"Common Stock","published_at":"2021-07-21T20:16:16.000Z","date":"2021-07-19","kind":"grant","acquired":true,"shares":1580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria."}],"balance_after":80818,"source":{"system":"sec-edgar","filing":"0000805928-21-000148","document":"wf-form4_162689855941312.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000148/wf-form4_162689855941312.xml","form_type":"4"}},{"id":2735128,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Clin. & Trans. Sciences"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-30T20:10:49.000Z","date":"2021-04-28","kind":"exercise","acquired":false,"shares":10000,"price":2.86,"value":28600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All shares pursuant to the employee stock option were fully vested on May 1, 2018 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vested on May 1, 2015 (12 months from the option grant date) and an additional 12.5% of the aggregate shares each 6 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":2.86,"exercise_date":"2015-05-01","expiration_date":"2021-05-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000805928-21-000076","document":"wf-form4_161981342959757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000076/wf-form4_161981342959757.xml","form_type":"4"}},{"id":2735127,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Clin. & Trans. Sciences"}}],"security":"Common Stock","published_at":"2021-04-30T20:10:49.000Z","date":"2021-04-28","kind":"exercise","acquired":true,"shares":10000,"price":2.86,"value":28600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person has elected to exercise and hold the shares at this time."}],"balance_after":78082,"source":{"system":"sec-edgar","filing":"0000805928-21-000076","document":"wf-form4_161981342959757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000076/wf-form4_161981342959757.xml","form_type":"4"}},{"id":2780309,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Restricted Stock Units","published_at":"2021-03-18T21:55:06.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":11800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":11800,"derivative":{"underlying":"Common Stock","underlying_shares":11800},"source":{"system":"sec-edgar","filing":"0000805928-21-000062","document":"wf-form4_161610449172937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000062/wf-form4_161610449172937.xml","form_type":"4"}},{"id":2780308,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Employee Stock Option (right to purchase)","published_at":"2021-03-18T21:55:06.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter."}],"balance_after":23500,"derivative":{"exercise_price":20.91,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0000805928-21-000062","document":"wf-form4_161610449172937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000062/wf-form4_161610449172937.xml","form_type":"4"}},{"id":2852441,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2021-02-18T22:26:20.000Z","date":"2021-02-17","kind":"tax_withholding","acquired":false,"shares":322,"price":18.7,"value":6021.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021."}],"balance_after":68082,"source":{"system":"sec-edgar","filing":"0000805928-21-000027","document":"wf-form4_161368715401383.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000027/wf-form4_161368715401383.xml","form_type":"4"}},{"id":2852440,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2021-02-18T22:26:20.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":1181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria."}],"balance_after":68404,"source":{"system":"sec-edgar","filing":"0000805928-21-000027","document":"wf-form4_161368715401383.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000027/wf-form4_161368715401383.xml","form_type":"4"}},{"id":2852439,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2021-02-18T22:26:20.000Z","date":"2021-02-17","kind":"tax_withholding","acquired":false,"shares":1542,"price":18.7,"value":28835.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021."}],"balance_after":67223,"source":{"system":"sec-edgar","filing":"0000805928-21-000027","document":"wf-form4_161368715401383.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000027/wf-form4_161368715401383.xml","form_type":"4"}},{"id":2852438,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2021-02-18T22:26:20.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":5050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria."}],"balance_after":68765,"source":{"system":"sec-edgar","filing":"0000805928-21-000027","document":"wf-form4_161368715401383.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592821000027/wf-form4_161368715401383.xml","form_type":"4"}},{"id":2929707,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-12-30T22:33:19.000Z","date":"2020-12-29","kind":"sale","acquired":false,"shares":371,"price":17.81,"value":6607.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":63240,"source":{"system":"sec-edgar","filing":"0001179110-20-012325","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020012325/edgar.xml","form_type":"4"}},{"id":2929706,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-12-30T22:33:19.000Z","date":"2020-12-27","kind":"grant","acquired":true,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of December 27, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This reflects the number of restricted stock units that became vested as of December 27, 2020."}],"balance_after":63611,"source":{"system":"sec-edgar","filing":"0001179110-20-012325","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020012325/edgar.xml","form_type":"4"}},{"id":2935469,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-12-22T20:22:53.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":147,"price":16.42,"value":2413.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":62111,"source":{"system":"sec-edgar","filing":"0001179110-20-012175","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020012175/edgar.xml","form_type":"4"}},{"id":2935468,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-12-22T20:22:53.000Z","date":"2020-12-18","kind":"grant","acquired":true,"shares":575,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of December 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This reflects the number of restricted stock units that became vested as of December 18, 2020."}],"balance_after":62258,"source":{"system":"sec-edgar","filing":"0001179110-20-012175","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020012175/edgar.xml","form_type":"4"}},{"id":2941196,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-12-17T21:41:17.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.81,"exercise_date":"2018-01-02","expiration_date":"2021-01-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001179110-20-012059","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020012059/edgar.xml","form_type":"4"}},{"id":2941195,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-12-17T21:41:17.000Z","date":"2020-12-15","kind":"tax_withholding","acquired":false,"shares":4373,"price":16.5,"value":72154.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule 16b-3."}],"balance_after":61683,"source":{"system":"sec-edgar","filing":"0001179110-20-012059","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020012059/edgar.xml","form_type":"4"}},{"id":2941194,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-12-17T21:41:17.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":15000,"price":4.81,"value":72150.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that became vested as of January 2, 2018."}],"balance_after":66056,"source":{"system":"sec-edgar","filing":"0001179110-20-012059","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020012059/edgar.xml","form_type":"4"}},{"id":3167829,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-04-29T21:56:23.000Z","date":"2020-04-28","kind":"exercise","acquired":true,"shares":2530,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.27,"exercise_date":"2014-06-09","expiration_date":"2020-06-09","underlying":"Common Stock","underlying_shares":2530},"source":{"system":"sec-edgar","filing":"0001179110-20-005269","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020005269/edgar.xml","form_type":"4"}},{"id":3167828,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-04-29T21:56:23.000Z","date":"2020-04-28","kind":"exercise","acquired":true,"shares":2530,"price":0.27,"value":683.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form is being filed to report the cash exercise of a stock option for a total of 2,530 shares."}],"balance_after":51056,"source":{"system":"sec-edgar","filing":"0001179110-20-005269","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020005269/edgar.xml","form_type":"4"}},{"id":3203634,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Restricted Stock Units","published_at":"2020-03-18T21:15:37.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date."}],"balance_after":12000,"derivative":{"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001179110-20-003913","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020003913/edgar.xml","form_type":"4"}},{"id":3203633,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Employee Stock Option (right to purchase)","published_at":"2020-03-18T21:15:37.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter."}],"balance_after":24000,"derivative":{"exercise_price":8.61,"expiration_date":"2030-03-16","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001179110-20-003913","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020003913/edgar.xml","form_type":"4"}},{"id":3261026,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-02-20T18:19:16.000Z","date":"2020-02-18","kind":"tax_withholding","acquired":false,"shares":351,"price":14.68,"value":5152.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020."}],"balance_after":48526,"source":{"system":"sec-edgar","filing":"0001179110-20-001943","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020001943/edgar.xml","form_type":"4"}},{"id":3261025,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-02-20T18:19:16.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":1181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria."}],"balance_after":48877,"source":{"system":"sec-edgar","filing":"0001179110-20-001943","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020001943/edgar.xml","form_type":"4"}},{"id":3261024,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-02-20T18:19:16.000Z","date":"2020-02-18","kind":"tax_withholding","acquired":false,"shares":1498,"price":14.68,"value":21990.64,"ownership":{"direct":true},"balance_after":47696,"source":{"system":"sec-edgar","filing":"0001179110-20-001943","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020001943/edgar.xml","form_type":"4"}},{"id":3261023,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2020-02-20T18:19:16.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":5049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria."}],"balance_after":49194,"source":{"system":"sec-edgar","filing":"0001179110-20-001943","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911020001943/edgar.xml","form_type":"4"}},{"id":3334618,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2019-12-20T21:27:34.000Z","date":"2019-12-18","kind":"tax_withholding","acquired":false,"shares":281,"price":16.73,"value":4701.13,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019."}],"balance_after":42840,"source":{"system":"sec-edgar","filing":"0001179110-19-013085","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911019013085/edgar.xml","form_type":"4"}},{"id":3334617,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2019-12-20T21:27:34.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":1150,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This reflects the number of restricted stock units that became vested as of December 18, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This reflects the number of restricted stock units that became vested as of December 18, 2019."}],"balance_after":43121,"source":{"system":"sec-edgar","filing":"0001179110-19-013085","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911019013085/edgar.xml","form_type":"4"}},{"id":3651945,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":59636,"kind":"person","name":"DeVinney Erick Wayne","position":1,"cik":"0001595972","reported_name":"DeVinney Erick Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical&Translational Sc"}}],"security":"Common Stock","published_at":"2019-02-19T18:24:16.000Z","date":"2019-02-15","kind":"tax_withholding","acquired":false,"shares":1498,"price":17.57,"value":26319.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2019."}],"balance_after":41971,"source":{"system":"sec-edgar","filing":"0001179110-19-002053","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/805928/000117911019002053/edgar.xml","form_type":"4"}}],"next_cursor":"2019-02-19T18:24:16.000000Z,3651945"}